Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Condensed Consolidated Statements Of Operations    
Revenues, net $ 147,724 $ 134,227
Operating expenses:    
Cost of implants and other costs 32,805 23,350
Research and development 59,006 8,231
Selling, general and administrative 591,422 506,600
Depreciation and amortization 3,446 8,389
Total operating expenses 686,679 546,570
Loss from operations (538,955) (412,343)
Other income (expenses):    
Interest expense, net (462,791) (9,761,505)
Loss on change in fair value of derivative liability (28,161,673)
Total other income (expenses) (462,791) (37,923,178)
Loss before income taxes (1,001,746) (38,335,521)
Income taxes
Net Loss $ (1,001,746) $ (38,335,521)
Net loss per common share, basic and diluted $ (0.00) $ (0.19)
Weighted average number of common shares outstanding, basic and diluted 246,270,452 202,611,873